What's new? Log in Free sign up

Corcept Therapeutics (CORT)

Company Profile

Company profile

Ticker

CORT

Exchange

Website

www.corcept.com

CEO

Dr. Joseph K. Belanoff M.D.

Incorporated

Location

Fiscal year end

Sector

Health Technology > Biotechnology

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co. • Alabama Power • Mississippi Power • Teva Pharmaceutical Industries Limited • Abbott Laboratories • Eli Lilly and • Bristol-Myers Squibb • Viatris ...

Former names

BANK SANTIAGO

SEC CIK

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

IRS number

770487658

CORT stock data

1M 3M 6M 1Y

Latest filings (excl ownership)

View all

Quarterly report

30 Oct 24

Corcept Therapeutics Announces Third Quarter Financial Results, Positive Results from Phase 3 Gradient Trial In Patients with Cushing’s Syndrome

Quarterly report

29 Jul 24

Corcept Therapeutics Announces Second Quarter Financial Results

Registration of securities for employees (post-effective amendment)

Registration of securities for employees (post-effective amendment)

Registration of securities for employees (post-effective amendment)

Registration of securities for employees (post-effective amendment)

Registration of securities for employees (post-effective amendment)

Transcripts

View all

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Latest ownership filings

View all

Daniel N Swisher JR

Notice of proposed sale of securities

Joseph Douglas Lyon

Gary Charles Robb

G LEONARD BAKER JR

Notice of proposed sale of securities

Notice of proposed sale of securities

Financial summary

Financial statements Chart CORT financial data

Quarter (USD)	Sep 24	Jun 24	Mar 24	Dec 23
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 23	Dec 22	Dec 21	Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Institutional ownership, Q3 2024

CORT institutional ownership history Ownership history

83.1% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	319	288	+10.8%
Opened positions	65	43	+51.2%
Closed positions	34	38	-10.5%
Increased positions	105	100	+5.0%
Reduced positions	103	111	-7.2%

13F shares	Current	Prev Q	Change
Total value	3.58 tn	2.52 tn	+41.8%
Total shares	87.08 mm	89.19 mm	-2.4%
Total puts	667.20 k	972.80 k	-31.4%
Total calls	1.12 mm	1.07 mm	+5.2%
Total put/call ratio	0.6	0.9	-34.8%

Largest owners	Shares	Value	Change
BlackRock	16.05 mm	$742.81 bn	NEW
Vanguard	10.01 mm	$463.09 bn	+4.7%
Ingalls & Snyder	8.27 mm	$382.59 mm	+0.3%
Renaissance Technologies	6.51 mm	$301.24 bn	-5.8%
Parallel Advisors	3.81 mm	$176.50 bn	-0.1%
STT State Street	3.52 mm	$162.87 bn	+0.6%
Dimensional Fund Advisors	2.53 mm	$117.19 bn	-5.4%
Novo Holdings A/S	2.41 mm	$111.60 bn	0.0%
Geode Capital Management	2.38 mm	$110.11 bn	+4.4%
Arrowstreet Capital, Limited Partnership	1.58 mm	$73.15 bn	+6.6%

Largest transactions	Shares	Bought/sold	Change
BLK BlackRock	0.00	-16.54 mm	EXIT
BlackRock	16.05 mm	+16.05 mm	NEW
Norges Bank	0.00	-822.12 k	EXIT
Man Group Limited	350.53 k	-479.41 k	-57.8%
Vanguard	10.01 mm	+452.62 k	+4.7%
Renaissance Technologies	6.51 mm	-403.57 k	-5.8%
Jacobs Levy Equity Management	1.22 mm	+352.95 k	+40.5%
Jupiter Asset Management	256.27 k	-284.43 k	-52.6%
FMR	1.36 mm	+269.07 k	+24.6%
Cambridge Investment Research Advisors	26.86 k	-259.40 k	-90.6%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

CORT insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
27 Jan 25	Wilson James N	Common Stock	Gift	Dispose G	Yes	No	0	7,800	0.00	1,445,168
22 Jan 25	Wilson James N	Common Stock	Other	Acquire J	Yes	No	0	146,742	0.00	1,452,968
22 Jan 25	Wilson James N	Common Stock	Gift	Dispose G	No	No	0	146,742	0.00	0
22 Jan 25	Wilson James N	Common Stock	Payment of exercise	Dispose F	No	No	59.03	103,258	6.10 mm	146,742
22 Jan 25	Wilson James N	Common Stock	Option exercise	Acquire M	No	No	3.29	250,000	822.50 k	250,000
22 Jan 25	Wilson James N	Stock option Common Stock	Option exercise	Dispose M	No	No	3.29	250,000	822.50 k	0
10 Jan 25	Daniel N Swisher JR	Common Stock	Sell	Dispose S	No	Yes	50.54	2,200	111.19 k	0
10 Jan 25	Daniel N Swisher JR	Common Stock	Option exercise	Acquire M	No	No	12.13	2,200	26.69 k	2,200
10 Jan 25	Daniel N Swisher JR	Stock option Common Stock	Option exercise	Dispose M	No	No	12.13	2,200	26.69 k	8,400
3 Jan 25	Gary Charles Robb	Common Stock	Option exercise	Acquire M	No	No	3.29	3,037	9.99 k	23,156

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

Corcept Therapeutics Presents Phase 3 Long-Term Extension Study Of Relacorilant Demonstrated Durable Cardiometabolic Improvements In Patients With Hypercortisolism

Results from Phase 3 long-term extension study of relacorilant to treat patients with hypercortisolism were presented at the World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)116

Corcept Therapeutics' FDA-Approved Korlym Hits Main Goal In Cushing's Syndrome Patients With Difficult-To-Control Diabetes

Corcept Therapeutics reports positive Phase 4 CATALYST results, showing Korlym significantly improves hemoglobin A1c in hypercortisolism patients.

Corcept Announces Primary Endpoint Met In Treatment Phase Of CATALYST Trial In Patients With Hypercortisolism And Difficult-To-Control Diabetes

Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by

Corcept Announces Results From Phase 2 Study Of Dazucorilant In Patients With Amyotrophic Lateral Sclerosis; DAZALS Did Not Meet Its Primary Endpoint, Which Was The Change From Baseline In The ALS Functional Rating Scale-Revised In Patients Who Received Dazucorilant Compared To Those Who Received Placebo

Press releases

From Benzinga Pro

Kuehn Law Encourages Investors of Corcept Therapeutics Inc. to Contact Law Firm

NEW YORK, Jan. 24, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Corcept Therapeutics Inc. (NASDAQ:CORT) breached their fiduciary

Corcept Submits New Drug Application for Relacorilant as a Treatment for Patients With Hypercortisolism

Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by

Corcept's Phase 3 Long-Term Extension Study of Relacorilant Demonstrated Durable Cardiometabolic Improvements in Patients with Hypercortisolism

Results from Phase 3 long-term extension study of relacorilant to treat patients with hypercortisolism were presented at the World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) 116

Corcept Announces Positive Results in Treatment Phase of CATALYST Trial in Patients With Hypercortisolism (Cushing's Syndrome) and Difficult-to-Control Diabetes

Corcept Announces Results From Phase 2 Study of Dazucorilant in Patients With Amyotrophic Lateral Sclerosis (ALS)

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.